Study links pregabalin to better sedation and pain control in cats

Pregabalin is getting a closer look as a perioperative add-on for cats. In a newly posted clinical trial in Frontiers in Veterinary Science, researchers reported that cats given oral pregabalin before ovariohysterectomy were more sedate before anesthesia and appeared more comfortable in the first hour after extubation than cats given placebo, without measurable differences in key physiologic parameters during surgery. (frontiersin.org)

The study lands at a time when feline pain control remains an active area of refinement rather than a settled protocol. International feline pain guidance has emphasized preventive, multimodal analgesia, cat-friendly handling, and the use of adjuvant drugs when appropriate, while also noting that more research is needed on newer or less-established adjuncts. In general practice, anesthetic and analgesic protocols for routine feline ovariohysterectomy still vary widely, which means even modest evidence for a simple oral add-on can draw attention. (pmc.ncbi.nlm.nih.gov)

According to the abstract, 54 cats were randomly assigned to pregabalin or control groups. The pregabalin group received 5 mg/kg orally 90 minutes before hospital admission, while controls received identical empty capsules. All cats then received the same multimodal anesthetic protocol: methadone and alfaxalone for premedication, propofol for induction, and isoflurane for maintenance. Sedation was measured with both a feline multiparametric sedation scale and a simple qualitative scale, and postoperative pain was assessed at 0, 15, 30, and 60 minutes after extubation using the Glasgow Feline Composite Measure Pain Scale short form and the Feline Grimace Scale. Pregabalin was associated with a 2.46-point increase in sedation scores and significantly lower postoperative pain scores across all measured time points, with no significant differences in monitored physiologic variables. (frontiersin.org)

The result is directionally consistent with what clinicians already know about this drug class, but it also highlights an important distinction: evidence for sedation and stress reduction in cats is stronger than evidence for perioperative analgesia. A 2025 feline therapeutics review described pregabalin as an extra-label adjunct for perioperative sedation and noted that stronger evidence exists for gabapentin-type drugs as sedatives and anxiolytics than as analgesics. That makes this new trial notable because it points to a possible dual benefit, calmer preoperative handling and less early postoperative pain, in a controlled ovariohysterectomy setting. (journals.sagepub.com)

There is also some supporting background from adjacent studies. Prior work has shown pregabalin can produce preanesthetic effects similar to gabapentin in cats, and another study found oral pregabalin reduced the minimum alveolar concentration of isoflurane in cats by roughly 18% to 24%, suggesting anesthetic-sparing potential. Those findings don't prove better clinical recovery on their own, but they help explain why interest in pregabalin has expanded beyond transport and appointment anxiety. (pubmed.ncbi.nlm.nih.gov)

Why it matters: For veterinary professionals, this study may be most relevant as a workflow and comfort story, not just a pharmacology story. An oral drug given before admission that improves preoperative sedation could make feline intake, catheter placement, and handling smoother for staff and less stressful for the pet parent and patient. If the same drug also reduces immediate postoperative pain scores without destabilizing intraoperative monitoring, it may strengthen multimodal protocols in high-volume spay settings or feline-focused practices. Still, the evidence is early, the reported pain window was short, and the article is currently available as an ahead-of-format version, so most clinicians will likely view it as promising rather than practice-changing. (frontiersin.org)

Another practical consideration is regulatory and labeling context. Pregabalin already has a marketed feline role for reducing fear and anxiety associated with transport and veterinary visits in some regions, which may make clinicians more familiar with the drug and its administration. But use as a perioperative analgesic adjunct for routine ovariohysterectomy is a different clinical question and, based on the available sources, remains outside a specifically approved surgical indication. That means protocol adoption will likely depend on clinician comfort with extra-label use, case selection, and whether future studies confirm benefit across broader populations and longer recovery periods. (journals.sagepub.com)

What to watch: The next signals to watch are the final formatted paper, larger trials with longer postoperative follow-up, head-to-head comparisons with gabapentin or other adjuncts, and whether future guidelines begin to cite pregabalin as a more established option in feline perioperative pain management. (frontiersin.org)